Development of Carboxyfullerene Drugs to Treat ALS

描述（由申请人提供）：研究表明，富勒烯基抗氧化剂是优秀的神经保护剂，并且它们在广泛的氧化性神经障碍模型中表现出良好的功效，包括肌萎缩性侧索硬化症（ALS）、帕金森病和缺血性中风引起的脑损伤。这些结果表明，神经保护药物是迄今为止富勒烯最独特，但重要和商业上可行的应用之一。 虽然它显示出作为神经保护药物的巨大前景，可用于治疗疾病，如ALS和帕金森病，对于这些疾病迫切需要更好的治疗，但衍生的富勒烯化合物目前太昂贵，并且不能以足够的量生产用于临床测试或治疗患者。在第一阶段，我们开发了几种新技术，可以有效地生产羧基富勒烯药物化合物。随着持续的发展，我们预计到项目完成时，将有可能经济地制造足够的富勒烯基神经保护剂，用于开始的临床试验。

DESCRIPTION (provided by applicant): Studies show that fullerene-based antioxidants make excellent neuroprotectants, and they have demonstrated good efficacy in models for a wide array of oxidative neurological disorders including arnyotrophic lateral sclerosis (ALS), Parkinson's disease and brain injury resulting from ischemic stroke. These results suggest that neuroprotective pharmaceuticals are one of the most unique, yet important and commercially viable applications of fullerenes to date. Although it shows great promise as a neuroprotectant drug useful in treating ailments such as ALS and Parkinson's disease for which better treatments are desperately needed, the derivatized fullerene compounds are currently too expensive and cannot be produced in sufficient quantities for clinical testing or to treat patients. During Phase I, we developed several new techniques that allow efficient production of a carboxyfullerene pharmaceutical compound. With continued development, we anticipate that by the completion of the project, it will be possible to economically manufacture enough of the fullerene- based neuroprotectant for clinical trials to begin.